# Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset

> **NCT07324837** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Supergene, LLC** · enrollment: 990 (estimated)

## Conditions studied

- Ischemic Stroke, Acute

## Interventions

- **DRUG:** non-immunogenic staphylokinase
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07324837
- **Lead sponsor:** Supergene, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-11-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 990 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07324837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07324837, "Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07324837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*